| UniProt/SwissProt ID: | H4_HUMAN |
| Description: | histone cluster 1, H4c [Source:HGNC Symbol;Acc:4787] |
| Location: | chr6 p22.2 |
| Node attribute: | gene |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| T74 | DAVTYtEHAKR | Histone | PhosphoSitePlus |
| T83 | KRKTVtAMDVV | Histone | PhosphoSitePlus |
| T83 | KRKTVtAMDVV | HPRD | |
| S2 | ____MsGRGKG | PhosphoSitePlus | |
| T81 | HAKRKtVTAMD | HPRD | |
| Y89 | AMDVVyALKRQ | Histone | PhosphoSitePlus |
| Y73 | RDAVTyTEHAK | Histone | PhosphoSitePlus |
| Y99 | QGRTLyGFGG_ | PhosphoSitePlus | |
| Y52 | ISGLIyEETRG | Histone | PhosphoSitePlus |
| T81 | HAKRKtVTAMD | Histone | PhosphoSitePlus |
| S48 | GVKRIsGLIYE | HPRD; phosphoELM; SysPTM | |
| S2 | RGKG | phosphoELM | |
| S48 | GVKRIsGLIYE | Histone | PhosphoSitePlus; SysPTM |
| Y52 | ISGLIyEETRG | HPRD; phosphoELM | |
| Y89 | AMDVVyALKRQ | HPRD; phosphoELM | |
| T31 | NIQGItKPAIR | Histone | PhosphoSitePlus |
| T55 | LIYEEtRGVLK | Histone | PhosphoSitePlus |
| Dephosphorylation site |
| H4_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000358162 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000350767 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000347168 | R96L | COSMIC | Ovarian Cancer | 21720365 | ENSP00000376663 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000353624 | E54D | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000367034 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000348258 | K13I | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000350767 | R37C | COSMIC | Ovarian Cancer | 21720365 | ENSP00000350767 | R40Q | COSMIC | Ovarian Cancer | 21720365 | ENSP00000343282 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000346316 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000353624 | R79H | COSMIC | Ovarian Cancer | 21720365 | ENSP00000367034 | A70T | COSMIC | Skin Cancer | 21984974 | ENSP00000358153 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000353624 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000353624 | N26I | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000352980 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000343282 | K9R | BIOMART | Breast Cancer | 21930507, 21930502 | ENSP00000366956 | V88F | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000366581 | R40M | COSMIC | Ovarian Cancer | 20826764 | ENSP00000347168 | R96L | TCGA | Ovarian Cancer | 21720365, 18772890 | ENSP00000366974 | R4K | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000289352 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000350159 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000366581 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000346316 | R24H | COSMIC | Pancreatic Cancer | 18772397 | ENSP00000366956 | S2C | COSMIC | Ovarian Cancer | 21720365 | ENSP00000366956 | R40G | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000347168 | G10R | COSMIC | Pancreatic Cancer | ENSP00000366956 | A16V | COSMIC | Ovarian Cancer | 21720365 | ENSP00000366974 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000366956 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000376668 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000348258 | D25N | COSMIC | Ovarian Cancer | 21720365 | ENSP00000366581 | R68W | COSMIC | Head and Neck Cancer | 21798893 | ENSP00000376664 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000347168 | E64Q | HPI | Breast Cancer | 16959974 | ENSP00000348258 | E64Q | Sjoblom2006, COSMIC, HPI | Breast Cancer | 16959974 | ENSP00000353624 | K80N | BIOMART | Breast Cancer | 21930507, 21930502 | ENSP00000376669 | E64Q | HPI | Breast Cancer | 16959974 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000376663 | Hepatocellular Carcinoma | Normal vs. Cancer | cell line | Up | 5.3 | 18646787 | ENSP00000376663 | Breast Cancer | Treatment (none vs. 17b-Estradiol treatment) | cell line | Up | 2.3 | 18491314 | ENSP00000376663 | Gastric Cancer | Treatment (none vs. drug-resistant) | cell line | Down | 0.53 | 20625496 |
| Hyperphosphorylation site |
| Site | Motif | Peptide | Cancer name | Pubmed | Source |
|---|---|---|---|---|---|
| Y73 | Histone | VIRDAVTyTEHAKRK | cholangiocellular carcinoma | 21253578 | PhosphoSitePlus |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| TMF1_HUMAN | H4_HUMAN | TF -> target gene | TRANSFAC |
| Function Annotation |
| KEGG Pathway |
| H4_HUMAN is not in KEGG pathway. |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0006352 | DNA-dependent transcription, initiation | IEA | biological_process |
| GO:0048015 | phosphatidylinositol-mediated signaling | NAS | biological_process |
| GO:0005730 | nucleolus | IDA | cellular_component |
| GO:0045653 | negative regulation of megakaryocyte differentiati | IDA | biological_process |
| GO:0015629 | actin cytoskeleton | IDA | cellular_component |
| GO:0005515 | protein binding | IEA | molecular_function |
| GO:0005576 | extracellular region | TAS | cellular_component |
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0034080 | CENP-A containing nucleosome assembly at centromer | TAS | biological_process |
| GO:0005634 | nucleus | IDA | cellular_component |
| GO:0000723 | telomere maintenance | TAS | biological_process |
| GO:0005654 | nucleoplasm | TAS | cellular_component |
| GO:0046982 | protein heterodimerization activity | IEA | molecular_function |
| GO:0003677 | DNA binding | TAS | molecular_function |
| GO:0006325 | chromatin organization | NAS | biological_process |
| GO:0000786 | nucleosome | TAS | cellular_component |
| GO:0006334 | nucleosome assembly | TAS | biological_process |